Mackenzie Financial Corp Purchases 1,074 Shares of STERIS plc (NYSE:STE)

Mackenzie Financial Corp raised its position in STERIS plc (NYSE:STE - Free Report) by 12.9% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 9,399 shares of the medical equipment provider's stock after purchasing an additional 1,074 shares during the period. Mackenzie Financial Corp's holdings in STERIS were worth $1,932,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Avalon Trust Co bought a new position in STERIS during the fourth quarter worth $30,000. Human Investing LLC acquired a new stake in STERIS during the 4th quarter worth about $31,000. Anfield Capital Management LLC raised its position in shares of STERIS by 100.0% in the 4th quarter. Anfield Capital Management LLC now owns 182 shares of the medical equipment provider's stock worth $37,000 after acquiring an additional 91 shares in the last quarter. Manchester Capital Management LLC lifted its stake in shares of STERIS by 182.7% in the 4th quarter. Manchester Capital Management LLC now owns 212 shares of the medical equipment provider's stock valued at $44,000 after purchasing an additional 137 shares during the period. Finally, Brown Brothers Harriman & Co. boosted its position in shares of STERIS by 66.7% during the 4th quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical equipment provider's stock valued at $45,000 after purchasing an additional 88 shares in the last quarter. Institutional investors and hedge funds own 94.69% of the company's stock.

STERIS Stock Down 1.4%

NYSE STE traded down $3.34 during mid-day trading on Monday, hitting $241.87. The company's stock had a trading volume of 501,697 shares, compared to its average volume of 544,806. The firm has a market capitalization of $23.76 billion, a price-to-earnings ratio of 51.35 and a beta of 0.96. The company's 50 day simple moving average is $228.42 and its 200 day simple moving average is $220.91. The company has a current ratio of 2.13, a quick ratio of 1.40 and a debt-to-equity ratio of 0.32. STERIS plc has a twelve month low of $200.98 and a twelve month high of $252.79.

STERIS (NYSE:STE - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The medical equipment provider reported $2.74 earnings per share for the quarter, beating analysts' consensus estimates of $2.59 by $0.15. The firm had revenue of $1.48 billion for the quarter, compared to analyst estimates of $1.47 billion. STERIS had a net margin of 8.66% and a return on equity of 13.91%. The business's quarterly revenue was up 5.7% compared to the same quarter last year. During the same period last year, the firm earned $2.58 earnings per share. Analysts anticipate that STERIS plc will post 9.08 earnings per share for the current year.

STERIS Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 26th. Shareholders of record on Tuesday, June 10th will be issued a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a yield of 0.94%. The ex-dividend date is Tuesday, June 10th. STERIS's dividend payout ratio is currently 36.77%.

Insider Transactions at STERIS

In other news, SVP Cary L. Majors sold 12,828 shares of the company's stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $250.08, for a total value of $3,208,026.24. Following the completion of the sale, the senior vice president now owns 11,372 shares in the company, valued at $2,843,909.76. This represents a 53.01% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 1.14% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Jefferies Financial Group initiated coverage on STERIS in a research note on Thursday. They issued a "hold" rating and a $263.00 price target on the stock. Morgan Stanley boosted their target price on shares of STERIS from $240.00 to $260.00 and gave the company an "equal weight" rating in a research report on Monday, May 19th. Stephens reissued an "overweight" rating and set a $250.00 target price on shares of STERIS in a research note on Thursday, May 15th. Wall Street Zen downgraded shares of STERIS from a "strong-buy" rating to a "buy" rating in a research note on Friday. Finally, Piper Sandler upped their price objective on shares of STERIS from $260.00 to $265.00 and gave the company an "overweight" rating in a report on Monday, February 3rd. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $263.83.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.